Go Deep
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,280 | 17.6 | 14.19 | 0.77 | 2,872.40 |
| Oct 2026 | 15,284 | 17.6 | 14.18 | 0.77 | 2,842.54 |
| Oct 2026 | 15,728 | 17.5 | 14.11 | 0.77 | 2,812.25 |
| Oct 2026 | 15,447 | 17.9 | 14.45 | 0.77 | 2,872.64 |
| Oct 2026 | 14,863 | 18.4 | 15.17 | 0.77 | 3,015.96 |
| Oct 2026 | 15,257 | 18.1 | 14.60 | 0.77 | 2,894.49 |
| Oct 2026 | 15,199 | 18.2 | 14.67 | 0.77 | 2,911.81 |
| Oct 2026 | 15,043 | 18.4 | 14.86 | 0.77 | 2,949.74 |
| Oct 2026 | 14,559 | 19.1 | 15.45 | 0.77 | 3,059.73 |
| Oct 2026 | 14,808 | 18.8 | 15.15 | 0.77 | 2,993.13 |
Caris Life Sciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 263,712,000.0 | 216,174,000.0 | 292,886,000.0 | 216,833,000.0 |
| Net Profit | -637,000.0 | -510,000.0 | 81,957,000.0 | 24,325,000.0 |
| EPS | 0.0 | 0.0 | 0.3 | 0.1 |
Caris Life Sciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 812,033,000.0 | 412,260,000.0 | 306,128,000.0 | 258,485,000.0 |
| Net Profit | -68,088,000.0 | -281,890,000.0 | -341,415,000.0 | -320,827,000.0 |
| EPS | -3.2 | -1.4 | -1.8 | -1.6 |
Caris Life Sciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 1,125,663,000.0 | 343,734,000.0 | 412,900,000.0 | 717,422,000.0 |
| Total Liabilities | 548,356,000.0 | 2,842,572,000.0 | 2,557,850,000.0 | 2,419,535,000.0 |
| Total Equity | 577,307,000.0 | -2,498,838,000.0 | -2,144,950,000.0 | -1,702,113,000.0 |
Owes vs Owns
Caris Life Sciences, Inc. owed $0.52 for every $1 it owned in Jun 2026, down from $3.37 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.49× | 8.27× | 6.19× | 3.37× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Caris Life Sciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 70.9%Receivables 10.0%Inventory 5.7%Fixed assets (tangible) 5.6%Intangible assets 1.7%Other assets 6.1%
How it's funded — Dec 2025
Short-term debt 0.6%Long-term debt 33.6%Payables 3.5%Other liabilities 11.0%Shareholders' equity 51.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 798.6 | 66.2 | 121.6 | 409.6 |
| Receivables | 112.1 | 88.2 | 55.3 | 40.2 |
| Inventory | 63.6 | 39.6 | 49.0 | 47.0 |
| Fixed assets (tangible) | 63.2 | 67.8 | 147.5 | 138.0 |
| Intangible assets | 19.3 | 19.3 | 19.3 | 19.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 68.8 | 62.6 | 20.2 | 63.2 |
| Liabilities & equity | ||||
| Short-term debt | 6.5 | 60.0 | 0.2 | 52.8 |
| Long-term debt | 378.4 | 319.2 | 166.1 | 169.6 |
| Payables | 39.2 | 27.8 | 26.7 | 27.3 |
| Other liabilities | 124.2 | 2,435.6 | 2,364.9 | 2,169.9 |
| Shareholders' equity | 577.3 | -2,498.8 | -2,144.9 | -1,702.1 |
| Net tangible assets | 558.0 | -2,518.2 | -2,164.3 | -1,721.5 |
Caris Life Sciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | 83,155,000.0 | -245,199,000.0 | -276,100,000.0 | -285,706,000.0 |
| Investing Activities | -16,260,000.0 | 52,932,000.0 | 214,774,000.0 | -282,986,000.0 |
| Financing Activities | 664,989,000.0 | 200,292,000.0 | 10,132,000.0 | 10,445,000.0 |